Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2018-06-06

FDA Approved: AUSTEDO — Supplemental Application (Teva Neuroscience, Inc.)

View source ↗

Summary

FDA approved a supplemental application for AUSTEDO (deutetrabenazine) filed by Teva Neuroscience, updating the drug's labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • AUSTEDO (deutetrabenazine)

Snippet

SUPPL AP for AUSTEDO (DEUTETRABENAZINE)